Clinical Implication {#S1}
====================

Patients with primary immunodeficiency are at an increased risk of cancer. Our case and literature review indicate an association between X-linked agammaglobulinemia and gastrointestinal malignancy and suggest that screening for gastrointestinal malignancy should occur for patients with X-linked agammaglobulinemia and gastrointestinal symptoms, unexplained anemia, or atrophic gastritis.

X-linked agammaglobulinemia (XLA) is an X-linked inherited disease caused by a germline mutation in the *BTK* gene leading to Bruton's tyrosine kinase deficiency, which results in the impaired development of B-lymphocytes and a subsequent lack of immunoglobulin production. Patients with XLA have an increased susceptibility to bacterial and viral infections, and multiple case reports have been published regarding an association between XLA and gastrointestinal (GI) malignancy.

Here, we describe a case of a 25-year-old man with XLA and HIV, who developed gastric adenocarcinoma. Previously reported cases of XLA and GI malignancy are also reviewed and summarized.

Case Report {#S2}
===========

A 25-year-old African-American man was referred to our center for continuous management of his XLA and HIV. At the age of 2 years, he started to develop recurrent infections, and based on a positive family history of XLA in a maternal uncle and several cousins, he was diagnosed with XLA and was started on intravenous immunoglobulin (IVIG) replacement since his diagnosis. Genetic testing was not initially done; however, recent genetic testing revealed a novel pathogenic variant in BTK c.307 C \> T p.Gln103Ter (Q103X). His course was complicated by several sinopulmonary infections requiring hospitalization. Due to high-risk sexual behavior, he was screened for Human Immunodeficiency Virus (HIV) and at the age of 23 years and was found to be positive for HIV with high viral load; viral serology was never obtained due to his baseline agammaglobulinemia. He was asymptomatic and was started on, highly active antiretroviral therapy (HAART) (elvitegravir/cobicistat/emtricitabine/tenofovir), which maintained his CD4 count \>1000 cells/mm^3^ and an undetectable viral load.

At the age of 24 years, he developed recurrent *Campylobacter jejuni* bacteremia and cellulitis of the leg, which was treated with meropenem for 4 weeks, subsequent episode was treated with a combination of intravenous meropenem and amikacin for 6 weeks. Suppressive doxycycline therapy was recommended, but the patient declined. Despite high-dose IVIG (700 mg/kg every 3 weeks), he continued to have immunoglobulin (Ig)G troughs (400--560 mg/dL). His stool culture, ova and parasite microscopic examination, and *Giardia* PCR were negative.

The patient had chronic iron-deficiency anemia and positive occult blood in his stool; therefore, an esophagogastroduodenoscopy (EGD) and colonoscopy were performed. His colonoscopy with random biopsy was normal. However, EGD showed gastric inflammation with erosions and ulceration. A gastric biopsy showed poorly differentiated gastric adenocarcinoma, which was *her2/neu* negative. The stain for *Helicobacter pylori* was positive. From a clinical stand point, except for his recurrent cellulitis, the patient did not have any other symptoms such as abdominal pain, early satiety, or weight loss. His review of systems as well did not reveal any respiratory symptoms. Abdominal computed tomography (CT) was negative for enlarged lymph nodes. However, a 1.4-cm arterially enhancing lesion in the left hepatic lobe was detected using abdominal and pelvic CT, with at least two adjacent sub-centimeter enhancing foci and two hepatic lesions. Abdominal magnetic resonance imaging characterized the larger lesion as hemangioma and the smaller lesions as cysts. Chest CT showed a 5-mm nodule, thought to be a granuloma. However, repeat CT scan of the lower lungs did not identify any nodules. His lungs otherwise were clear with no evidence of bronchiectasis or any other interstitial process. Genetic testing for CDH1 gene mutations, which are associated with hereditary diffuse Gastric cancer, was negative. He underwent subtotal gastrectomy, lymphadenectomy, and Roux-en-Y gastrojejunostomy. His post-operative pathology showed moderately poor differentiation of the adenocarcinoma with a signet ring component that was primarily mucosal with focal submucosal invasion, 0/20 nodes, negative margins, and diffuse metaplasia as well as omentum negative. Staining was positive for *H. pylori*.

His final diagnosis was stage 1A gastric cancer. No further treatment was recommended, and he was placed under surveillance with no evidence of malignant recurrence. However, he subsequently developed one episode of *C. jejuni* bacteremia that was treated with intravenous antibiotics.

Esophagogastroduodenoscopy was performed 1 year later and was negative for any ulcerations or concerning signs of recurrence.

Discussion {#S3}
==========

Patients infected with HIV are at increased risk of certain malignancies, including breast, anal, cervical, lung, colorectal, prostate, and hepatocellular carcinoma ([@B1]). However, gastric cancer has not been reported to have increased prevalence among HIV-infected patients. Our patient did not have an acquired immune deficiency syndrome (AIDS)-defining clinical condition. On the other hand, patients with antibody deficiency are at greater risk of lymphoma and GI malignancy ([@B2]). The increased incidence of stomach cancer in patients with common variable immunodeficiency disorders could be related to the high frequency of achlorhydria.

In our literature review of GI malignancy and XLA, we found a total of 15 cases of GI malignancy (5 cases of gastric adenocarcinoma, 9 cases of colorectal carcinoma, and 1 case of liver cancer) in addition to our reported case (Table [1](#T1){ref-type="table"}).

###### 

**Review of the literature regarding patients with gastrointestinal (GI) malignancy and X-linked agammaglobulinemia**.

  Case                           Country        Presenting GI symptoms                                                Histology                                 Anemia          IgG (mg/dL) on IVIG   Solid tumor                              Stage   Age (years)   Outcome
  ------------------------------ -------------- --------------------------------------------------------------------- ----------------------------------------- --------------- --------------------- ---------------------------------------- ------- ------------- ---------
  Adachi et al. ([@B3])          Japan          Diarrhea; frequent urge to defecate                                   NA                                        NA              95                    Colorectal                               Local   22            Alive
  Sasi et al. ([@B4])            Saudi Arabia   Loss of appetite, weight loss, diarrhea, right-sided abdominal pain   NA                                        NA              NA                    Necrotizing enterocolitis of the colon   Mets    10            Dead
  Bachmeyer et al. ([@B5])       France         Vomiting, dysphagia                                                   Chronic atrophic gastritis, negative HP   NA              235--450              Gastric                                  NA      26            NA
  Staines Boone et al. ([@B6])   Mexico         Phlebitis of the right leg, weight loss                               Gastric ulcer                             Megaloblastic   625                   Gastric                                  End     30            Dead
  Brosens et al. ([@B7])         Netherlands    Malabsorption, weight loss                                            NA                                        NA              NA                    Colorectal                               Local   45            Alive
  Brosens et al. ([@B7])         Netherlands    Weight loss                                                           Positive HP                               NA              NA                    Colorectal                               Local   37            Alive
  Chisuwa et al. ([@B8])         Japan          NA                                                                    NA                                        NA              NA                    Colorectal                               NA      NA            NA
  Kinlen et al. ([@B2])          UK             NA                                                                    NA                                        NA              NA                    Gastric                                  End     25            Dead
  Lackmann et al. ([@B9])        Germany        Sensory deficit in the left leg, B12 deficiency                       Negative HP; atrophic gastritis           Megaloblastic   172                   Gastric                                  Early   15            Alive
  Lavilla et al. ([@B10])        Spain          Vomiting, diarrhea, weight loss                                       Atrophic gastritis                        Megaloblastic   479                   Gastric                                  Mets    23            Alive
  Our case                       USA            Cellulitis of the leg                                                 Positive HP                               NA              400--560              Gastric                                  1A      25            Alive
  Vajdic et al. ([@B11])         Australia      NA                                                                    NA                                        NA              NA                    Gastric                                  NA      45            NA
  Van der Meer et al. ([@B12])   Netherlands    NA                                                                    NA                                        NA              NA                    Colorectal                               NA      36            Dead
  Van der Meer et al. ([@B12])   Netherlands    Abdominal distension, cramps, diarrhea                                Villous atrophy                           Microcytic      600                   Colorectal                               NA      NA            Dead
  Van der Meer et al. ([@B12])   Netherlands    Diarrhea, abdominal cramps, weight loss                               NA                                        NA              Undetectable          Colorectal                               NA      NA            Dead
  Van der Meer et al. ([@B12])   Netherlands    Diarrhea, abdominal cramps                                            NA                                        NA              NA                    Colorectal                               NA      36            Dead

*IgG, immunoglobulin G; IVIG, intravenous immunoglobulin; HP, Helicobacter pylori*.

The median age of male patients was 30 years (range, 7--40 years), indicating early onset of GI malignancy in patients with XLA. In the general population, the average age at diagnosis is 69 years, according to the American Cancer Society, and more than 80% of diagnosed cases of colorectal cancer occur in patients older than 55 years, according to a US task force.

Our patient had *C. jejuni* bacteremia, gastric inflammation, and *H. pylori* infection. He continued to have low IgG levels despite increasing the IgG replacement dose and frequency. We looked for a similar pattern in previously reported cases. Nine of the 16 patients had IgG levels \<700 mg/dL, and 6 of these patients had levels \<500 mg/dL, despite IVIG replacement. Two of the reported cases were positive for *H. pylori*, two were positive for *C. jejuni* bacteremia, two were infected with *Giardia lamblia*, and a majority had chronic atrophic gastritis. We hypothesized that chronic gastritis, with or without *H. pylori* infection, results in chronic inflammation, which could increase IgG catabolism or GI losses.

The anemia and positive occult blood in the present patient prompted the GI workup that led to his diagnosis. Three of the previously reported patients had megaloblastic anemia, and one patient had microcytic anemia. Chronic gastric inflammation can lead to achlorhydria, which in turn leads to megaloblastic anemia; this might be linked with gastric carcinoma in patients with common variable immunodeficiency ([@B2]) or XLA ([@B6]).

Finally, we reviewed the literature for the presenting signs and symptoms that support a diagnosis of GI malignancy; 10 of the 16 reported patients with XLA, who were diagnosed with GI malignancy, presented with weight loss or abdominal complaints such as diarrhea, a frequent urge to defecate, abdominal distension, cramping, and vomiting, which likely initiated the GI workup and led to an early diagnosis of GI malignancy. While there are many intestinal complications of antibody deficiencies, this one should be kept on the differential owing to its potential severity and treatability.

In conclusion, our case and review of the previous literature indicate an increased risk of GI malignancy in patients with XLA. The fact that our patient was HIV infected could have increased his risk of malignancy in general, although medical literature does not suggest particularly increased the risk of gastric cancer among HIV-infected patients. We found the presence of *H. pylori* infection and megalobastic anemia to be associated with GI malignancy in XLA, and since those could be detected in non-invasive ways (via urea breath test and B12 levels, respectively) we suggest screening for those factors in all patients with XLA and if present, this should prompt physicians to initiate a workup for GI malignancy in those patients.

Finally, we would like to note that our patient developed gastric cancer at the age of 23 years, Lackmann et al. described a 10-year-old boy with XLA and gastric cancer ([@B9]), and all cases summarized in Table [1](#T1){ref-type="table"} were below the age of 40 years, pointing out to the early onset of gastric cancer in this pediatric-onset disease, and that long-term follow-up for such patients raise the awareness about complications to be sought in this disease. Further studies to evaluate the cost-effectiveness of early screening for GI malignancy in patients with XLA might be warranted.
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